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We herein report a 59-year-old male patient with a recurrent carcinoid tumor of the middle ear 7 years after a
tympanomastoidectomy. The CT and dynamic MRI demonstrated an extensive tumor close to the carotid artery canal and the
jugular bulb, and the tumor was removed by a partial petrosectomy with a transmastoid approach. The histopathological ﬁndings
revealed a solid and trabecular tumor with cells positive for cytokeratin, chromogranin A, synaptophysin, and CD56. The MIB-1
antibody for the Ki-67 antigen was positive in 6.6% of the tumor cells. The relevant literature is reviewed in regard to the present
case.
1.Introduction
Carcinoid tumors primarily originate from gastrointestinal
organs and the trachea. Carcinoid tumors of the middle
ear are very rare; however, there have been more than
50 reports of such tumors since 1980 [1]. A middle-ear
carcinoid tumor is usually conﬁned to the tympanum, and
osteolytic extension of the tumor is rare [2]. Several patients
showosteolyticinvasionandcervicallymphnodemetastasis,
suggesting that the middle-ear carcinoid should be classiﬁed
asalow-grademalignancy[3–5].Thecurrentreportpresents
a patient with extensive osteolytic enlargement of a middle-
ear carcinoid close to the jugular bulb and carotid artery
canal, and also reviews the previous studies of carcinoid
tumors of the middle ear.
2.CaseReport
A 59-year-old male patient presented with ear pain and
bleeding of the left ear, and upon closer investigation a
reddish bulging mass extending through the left tympanic
membrane from the middle ear was observed. The pure tone
audiogram showed an 80-dB mixed hearing loss with an
increased threshold of bone conduction in the high tone
frequency range. The patient experienced no dizziness or
facial palsy. The tympanum and mastoid were ﬁlled with
an isodensity shadow indicating bone erosion, and the wall
of the carotid artery canal and the jugular bulb appeared
to be thick and erosive on CT (Figure 1). The mass was
close to the carotid artery and jugular bulb through the
tympanum, and the mastoid space was enhanced in the
early and late phases of the dynamic MRI. The enhanced
mass also appeared on the underside of the promontory of
the middle ear (Figure 2). The patient had experienced a
tympanomastoidectomyfortumorsinthetympanum7years
previously and the pathological diagnosis was adenoma of
the middle ear.
The surgical ﬁndings revealed that a grayish-red tumor
with a slight yellowish hue ﬁlled the mastoid. The upper
construction of the stapes was conservative, although it
was covered with granulation. We performed a canal wall-
down mastoidectomy to expose the sigmoid sinus, which2 International Journal of Otolaryngology
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Figure 1: CT. The tympanum and mastoid were ﬁlled with an isodensity shadow with bone erosion. The wall of the carotid artery and
jugular bulb appeared to be thick and erosive. CA: carotid artery, JB: jugular bulb, TMJ: temporomandibular joint, EAC: external auditory
canal, VII: the seventh nerve, PP: Petrous pyramid.
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Figure 2: Dynamic enhanced MRI. The mass close to the carotid artery and jugular bulb through the tympanum and mastoid was enhanced
in the early phase of the dynamic MRI (white arrows).
revealed the tumor mass close to the jugular bulb. The
tumor had originated from the mucous membrane of the
hypotympanumandprogressedtodestroythebonyportions
of the posterior wall of the extra meatus through the
underside of the cochlear promontory with communication
between the hypotympanum and mastoid. There was bone
erosion in the tympanic portion of the facial nerve canal,
but no invasion to the facial nerve and jugular bulb was
observed. Removal of the bony annulus and the residual
tumors in the hypotympanum revealed the internal carotid
artery with bony erosion, and the tumor was completely
removed, sparing facial nerve.
The histopathological ﬁndings showed a solid sheet
of homogenous cells, which was surrounded by a ﬁbrous
border. The tumor cells had round, oval, or slightly irregular
nuclei with ﬁnely-dispersed chromatin, and occasionally
formed glandular or tubular structures (Figures 3(a) and
3(b)). They were typically positive for cytokeratin, chromo-
granin A, synaptophysin, and CD56, but were negative for S-
100.Theproliferativecapacityofthetumorcellswasassessed
by observing the cells expressing the marker MIB-1, which is
an antibody against antigen Ki-67. This was used to calculate
the proliferation index for each tumor lesion by counting
the total number of tumor cell nuclear proﬁles and the
number of MIB-1-positive nuclear proﬁles in randomly and
systematically selected ﬁelds. The ﬁrst ﬁeld in each tumor
lesion was selected randomly, and the following ﬁelds were
sampled systematically using a mesh [6]. The positive rate
of MIB-1 was 6.6% (Figure 3). The tumor was diagnosed as
carcinoid tumor based on these pathological ﬁndings.
3. Discussions
Murphy described the ﬁrst case of a carcinoid tumor of
the middle ear in 1980 [1], and approximately 50 cases of
middle-ear carcinoid have been reported since. More than
90% of the patients complain of hearing loss, and 20%–
30% of patients suﬀer from ear fullness, tinnitus, and ear
discharge. They usuallypresent with conductive hearing loss,
whereas a few subjects had sensorineural hearing loss, as
appearedinthepresentpatient.Transientfacialnervepalsyis
rarelyobserved.Acarcinoidtumorgenerallydevelopsslowly,
and the average disease duration is as long as 28 months
[7].International Journal of Otolaryngology 3
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Figure 3: Pathological ﬁndings. The histopathological ﬁndings revealed a solid tubuloglandular pattern, resembling an adenomatous tumor
of the middle ear ((a) examination on low power). One cell type, the A-type cells lining the glandular lumina, was observed with a lower
frequency. These slender darkly staining cells had the appearance of endothelial cells. The other cells, the B-type cells, were observed in
glandular structures and were characterized by a round or oval nucleus and an abundant, pale cytoplasm ((b) examination on high power).
The B-type cells were typically positive for cytokeratin, chromogranin A, and synaptophysin, and 6.6% of the carcinoid tumor cells were
positive for MIB-1 staining.
A carcinoid tumor shows an isodensity shadow equiva-
lenttotheotitismediaandcholesteatomaonCT.Acarcinoid
rarely shows osteolytic local-regional spread and destruc-
tion of the ossicles, which are helpful for diﬀerentiating
the carcinoid from adenocarcinomas and cholesteatomas.
However, patients with extensive osteolytic spread of a
middle-ear carcinoid as in the current subject have been
reported [3, 4, 8, 9]. The MRI ﬁndings of the carcinoid
tumors may not be useful for diﬀerentiation from other
inﬂammatory diseases and other tumors; however, dynamic
enhanced MRI in the present case showed carcinoid tumors
to be enhanced earlier after the administration of Gd than
granulation and other types of normal tissue. In addition,
dynamic enhanced MRI has been reported to be useful for
the diﬀerentiation of tumor recurrence and posttreatment
ﬁbrosis in regions other than the head and neck [10].
Recent studies demonstrated that dynamic enhanced MRI
is valuable for the diﬀerentiation of posttreatment ﬁbrosis
and tumor recurrence in the head and neck regions, as
in other regions [11, 12]. Therefore, our case report also
supports the ﬁnding that dynamic enhanced MRI is helpful
fordetectingthelocalextensionofmiddle-earcarcinoidsand
is valuable for diﬀerentiation of tumor recurrence and post-
treatment ﬁbrosis. Nuclear modalities such as scintigraphy
with octreotide and PET scanning are also clinically eﬃcient
for detecting the recurrence and metastasis of carcinoid
tumors [13, 14].
The pathological diagnosis of carcinoid tumors is based
onlightmicroscopyandisconﬁrmedbyimmunohistochem-
ical evaluation for diﬀerential diagnoses including adenoma,
paraganglioma, and adenocarcinoma. However, it is not
alwayseasytodistinguishbetweenmiddle-earcarcinoidsand
middle-ear adenomas. One report noted that it is therefore
reasonable to regard both tumors as two faces of a single
tumor type [15]. The histology of middle-ear carcinoids
is similar to other carcinoids, and shows a solid sheet of
monotonous cells surrounded by a ﬁbrous border. The
tumor cells, which have round, oval, or slightly irregular
nuclei with ﬁnely-dispersed chromatin occasionally form
glandular or tubular structures. They are strongly positive
for cytokeratin, which is an epithelial tumor marker, and
for neuroendocrinological markers such as chromogranin
A, synaptophysin, CD56, and vimentin, but are negative
for S-100. These tendencies are helpful for diﬀerentiating
such tumors from paraganglioma, because paraganglioma is
usually positive for S-100 [2, 16].
Most of the typical carcinoid tumors do not show a
proliferative index detected by Ki-67 labeling using MIB-1
indices exceeding 10%, and mostsmall-cellcarcinomasshow
substantially higher values than 25% [17–19]. The MIB-1
positive rate in the current case was 6.6%, thus resulting in
a diagnosis of a typical carcinoid.
The complete removal by a tympanomastoidectomy or
radical mastoidectomy is considered the optimal treatment4 International Journal of Otolaryngology
for middle-ear carcinoid tumors. However, there is no
established approach to therapy for middle-ear carcinoids
because of the small number of cases. A conservative local
resection is reported to be suﬃcient for patients with small-
bowel carcinoid tumors (less than 2cm) [20]. The middle-
ear carcinoid tumors are generally circumscribed; therefore,
the basic principles in treating middle-ear carcinoid tumors
may be similar to the treatments for small carcinoid tumors
of other organs.
Although local invasion of the middle-ear carcinoid
is usually slow and nondestructive, 4 reported patients
underwent surgical treatments by petrosectomy for the
invaded tumors with extensive enlargement. One patient was
initially treated with a petromastoidectomy for a tumor in
the hypotympanicum extending into the external auditory
canal without bone destruction [8], and another patient
initially underwent a partial petrosectomy for the removal
of middle-ear tumors extending into the hypotympanicum
with partial erosion of the stapes superstructure [9]. Knerer
et al. described surgical treatment by extended subtotal
petrosectomy for an extensive recurrent tumor with a close
relationship to the tegmen tympani, facial nerve, and the
ascending and horizontal portions of the carotid canal [3].
Menezes et al. performed a craniotomy, petrosectomy, neck
dissection, and parotidectomy for a recurrent carcinoid
tumor, but the carcinoid tumor recurred within 3 months
after the surgery [4]. In the present case, the carcinoid tumor
was close to the carotid artery and jugular bulb through
its large extension involving the residual hypotympanic
peritubal and perilabyrinthine cells. Radical resection of the
carcinoid tumor was possible by a partial petrosectomy,
furthermore sparing the facial nerve.
To date, adjuvant radiotherapy was administered in
aggressive cases with middle-ear carcinoid tumors, but the
clinical eﬃcacy of this treatment modality has not yet been
established [3–5, 7]. Our patient therefore underwent no
adjuvant radiotherapy.
Six of 34 reported patients that underwent surgical
treatment had a recurrence of the carcinoid tumor of the
middle ear, and the average length of time between the initial
treatment and the reappearance of the recurrent lesion was
200months. Thelengthoftime betweenthe initial treatment
with a tympanomastoidectomy or radical mastoidectomy
and the recurrence was relatively long (approximately 15–33
years) [7]. These results suggest that an extended follow-up
period is necessary, even in patients where a nearly complete
resection was performed, since carcinoid tumors of middle
ear slowly increase in size.
Regional metastatic disease occurred several years after
the initial treatment in 5 patients, including 2 patients with
metastases to the intraparotid gland lymph nodes, and 3
patients with metastases to the cervical lymph nodes. All
cases were surgically managed with a parotidectomy or a
neck dissection [4, 5, 7, 21]. However, one subject with
an intraparotid gland lymph node metastasis underwent a
craniotomy for the extended invasion to the intracranial
and infratemporal fossa. No distant metastases of middle-
ear carcinoid tumors have been reported. Therefore, middle-
ear carcinoid tumors should be approached as low-grade
malignanttumors[22],especiallywhenassessingthecervical
node status during the follow-up period.
The 10-year survival rates for patients with carcinoid
tumors and atypical carcinoid tumors among neuroen-
docrine tumors are 90% and 50%, respectively, whereas the
survival rate is only 5% for patients with small-cell carci-
nomas. The distinction of a carcinoid tumor from small-
cell carcinoma is critical because of major diﬀerences in the
management and prognosis. There is a strong correlation
between the proliferative index detected by Ki-67 labeling
using MIB-1 and the grade of the tumor [23]. There is also
a similar correlation between low Ki-67 values and longer
survival in carcinoid tumors, but no clear cutoﬀ value has
been deﬁned [23–26]. S ¸ahan et al. reported that the Ki-67
labelingindexwaslessthan1%inapatientwithamiddle-ear
carcinoid [13]. As compared with the present case, the Ki-67
index was found to be 6.6% and appeared to show higher
mitotic activity. The index may be a signiﬁcant predictor for
probability of osteolytic enlargement, local recurrence, and
regional metastases of middle-ear carcinoids.
4. Conclusions
The present report describes the case of a 59-year-old male
patient who presented with a carcinoid tumor of the middle
ear, and a partial petrosectomy was performed because the
tumor had extended to the carotid artery canal and jugular
bulb with bone erosion. A carcinoid tumor of the middle
ear is not generally considered to represent a malignancy,
but should be considered in the diﬀerential diagnosis of low-
grade malignancies.
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